Skip to main content
TipRanks
Go Ultimate75% OFF

Kura Oncology (KURA) Stock Price & Analysis

973 Followers

KURA Stock Chart & Stats

$7.34-$0.15(-2.00%)
At close: 4:00 PM EST
$7.5$10$12.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$7.32 - $8.18
52-Week Range
$6.75 - $13.90
Previous Close
$7.49
Volume
N/A
Average Volume (3M)
2.26M
Market Cap
$688.17M
Enterprise Value
$495.67M
Total Cash (Recent Filing)
$492.10M
Total Debt (Recent Filing)
$25.83M
Price to Earnings (P/E)
―
Beta
1.52
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Adoption

Rapid growth in product revenue, patient starts, and prescriptions indicates strengthening commercial adoption rather than reliance on a single initial launch wave. Expanding utilization can build a larger treated base, improve recurring refill potential, and support a more durable oncology franchise.

Market Position

Holding majority share in the targeted menin inhibitor market suggests meaningful physician preference and an early competitive position in a genetically defined cancer segment. This leadership can support durable prescribing relationships as treatment adoption expands and additional indications develop.

Funding Runway

Substantial liquidity and expected partner payments provide resources to fund commercialization and multiple clinical programs through important development milestones. Greater financing visibility reduces near-term dependence on a single capital raise while allowing continued investment in ziftomenib and darlafarnib.

Bears Say

Persistent Losses

Large operating and net losses show that revenue growth has not yet translated into economic breakeven. Continued investment in commercialization and clinical development may require substantial external funding, while the cost structure could remain a durable constraint on future earnings and cash generation.

Balance-sheet Erosion

The sharp decline in equity has materially reduced financial flexibility and made existing debt more significant relative to the capital base. Higher leverage can constrain strategic choices, increase reliance on future financing, and leave the company less resilient if clinical or commercial execution weakens.

Competitive And Data Risk

Unmatured duration data make the long-term commercial profile less certain, while competing menin inhibitors and reported safety considerations may affect prescribing decisions. Kura must continue demonstrating durable benefit and differentiation to defend share as the therapeutic market develops.

Kura Oncology News

KURA FAQ

What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.75 and its highest was $13.90 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $688.17M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 97 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 10, 2026. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.82 by $0.04.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.83.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 91,878,690 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.82. Following the earnings report the stock price went up 2.114%.
Which hedge fund is a major shareholder of Kura Oncology?
Hedge funds hold Kura Oncology shares: the largest hedge-fund position in Kura Oncology is 72,325,665 shares, and hedge funds increased their holdings by 1.4M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology